Last reviewed · How we verify
Eszopiclone 1 mg- Elderly
Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to promote sleep onset and maintenance.
Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to promote sleep onset and maintenance. Used for Insomnia in elderly patients (sleep onset and sleep maintenance).
At a glance
| Generic name | Eszopiclone 1 mg- Elderly |
|---|---|
| Also known as | SEP-190 |
| Sponsor | Eisai Co., Ltd. |
| Drug class | Nonbenzodiazepine hypnotic (Z-drug) |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology / Sleep Medicine |
| Phase | Phase 3 |
Mechanism of action
Eszopiclone is the active S-enantiomer of zopiclone and acts as a positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) in the central nervous system. This potentiation of GABAergic neurotransmission results in sedative, hypnotic effects that facilitate sleep initiation and consolidation. The elderly formulation is specifically dosed at 1 mg to account for age-related pharmacokinetic changes and reduced drug clearance in older populations.
Approved indications
- Insomnia in elderly patients (sleep onset and sleep maintenance)
Common side effects
- Headache
- Dizziness
- Somnolence
- Unpleasant taste
- Anxiety
- Hallucinations
- Complex sleep behaviors
Key clinical trials
- Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients
- Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients
- A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia (PHASE4)
- A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eszopiclone 1 mg- Elderly CI brief — competitive landscape report
- Eszopiclone 1 mg- Elderly updates RSS · CI watch RSS
- Eisai Co., Ltd. portfolio CI